Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Teva Pharmaceutical Industries : Unit Launches Generic Version of Soolantra Cream for Rosacea Treatment

06/16/2021 | 08:08am EDT


ę MT Newswires 2021
All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
08/03IMMUNEERING : Announces Closing of its Upsized Initial Public Offering and Exerc..
AQ
07/28ADRs Close Higher; Teva Trades Actively
DJ
07/28TEVA PHARMACEUTICAL INDUSTRIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCI..
AQ
07/28Teva Pharmaceutical Up Over 13%, on Pace for Largest Percent Increase Since N..
DJ
07/28UPDATE : Teva Pharmaceutical Reports Higher Adjusted Profit, Revenue in Q2, Shar..
MT
07/28Teva profit rise misses forecasts, sees lower 2021 sales
RE
07/28TEVA PHARMACEUTICAL INDUSTRIES : Reports Higher Adjusted Profit, Revenue in Q2, ..
MT
07/28TEVA PHARMACEUTICAL INDUSTRIES : Reports Second Quarter 2021 Financial Results (..
PU
07/28TEVA PHARMACEUTICAL INDUSTRIES : Generic Medicines Saved the United States $28.8..
BU
07/28TEVA PHARMACEUTICAL INDUSTRIES LTD : Results of Operations and Financial Conditi..
AQ
More news
Financials (USD)
Sales 2021 16 218 M - -
Net income 2021 1 074 M - -
Net Debt 2021 21 871 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Capitalization 10 941 M 10 941 M -
EV / Sales 2021 2,02x
EV / Sales 2022 1,86x
Nbr of Employees 37 736
Free-Float 90,3%
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 9,92 $
Average target price 12,21 $
Spread / Average Target 23,1%
EPS Revisions
Managers and Directors
Kňre Schultz President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Hafrun Fridriksdottir Executive VP-Global Research & Development
Eric DrapÚ Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED2.80%10 941
JOHNSON & JOHNSON10.81%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.24.10%246 075
NOVARTIS AG0.14%225 528
ELI LILLY AND COMPANY51.62%224 166